CN102802629A - 取代的4-羟基嘧啶-5-甲酰胺 - Google Patents
取代的4-羟基嘧啶-5-甲酰胺 Download PDFInfo
- Publication number
- CN102802629A CN102802629A CN2010800287783A CN201080028778A CN102802629A CN 102802629 A CN102802629 A CN 102802629A CN 2010800287783 A CN2010800287783 A CN 2010800287783A CN 201080028778 A CN201080028778 A CN 201080028778A CN 102802629 A CN102802629 A CN 102802629A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- alkyl
- pharmacy
- acceptable salt
- substituent group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (16)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22178909P | 2009-06-30 | 2009-06-30 | |
US61/221,789 | 2009-06-30 | ||
US23749109P | 2009-08-27 | 2009-08-27 | |
US61/237,491 | 2009-08-27 | ||
PCT/US2010/039289 WO2011002623A1 (en) | 2009-06-30 | 2010-06-21 | Substituted 4-hydroxypyrimidine-5-carboxamides |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102802629A true CN102802629A (zh) | 2012-11-28 |
Family
ID=43411372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800287783A Pending CN102802629A (zh) | 2009-06-30 | 2010-06-21 | 取代的4-羟基嘧啶-5-甲酰胺 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8815865B2 (zh) |
EP (1) | EP2448583B1 (zh) |
JP (1) | JP2012532127A (zh) |
CN (1) | CN102802629A (zh) |
AU (1) | AU2010266558A1 (zh) |
CA (1) | CA2766056A1 (zh) |
MX (1) | MX2011013878A (zh) |
WO (1) | WO2011002623A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2448584B1 (en) * | 2009-06-30 | 2014-12-31 | Merck Sharp & Dohme Corp. | Substituted 4-hydroxypyrimidine-5-carboxamides |
EP2560655B1 (en) * | 2010-04-21 | 2016-08-24 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
WO2013036676A1 (en) | 2011-09-06 | 2013-03-14 | New York Blood Center, Inc. | Hiv inhibitors |
US9034851B2 (en) | 2011-09-23 | 2015-05-19 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
TW201400458A (zh) | 2012-03-30 | 2014-01-01 | Daiichi Sankyo Co Ltd | (2-雜芳基胺基)琥珀酸衍生物 |
US10137107B2 (en) | 2014-09-19 | 2018-11-27 | New York Blood Center, Inc. | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV |
WO2016054804A1 (en) * | 2014-10-10 | 2016-04-14 | Merck Sharp & Dohme Corp. | Substituted pyrimidines as inhibitors of hif prolyl hydroxylase |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070072876A1 (en) * | 2005-09-15 | 2007-03-29 | Orchid Research Laboratories Ltd. | Novel pyrimidine carboxamides |
US7323475B2 (en) * | 2003-06-06 | 2008-01-29 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
US20080171756A1 (en) * | 2007-01-12 | 2008-07-17 | Shaw Antony N | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
US8409473B2 (en) | 2007-01-30 | 2013-04-02 | Evident Technologies, Inc. | Group II alloyed I-III-VI semiconductor nanocrystal compositions and methods of making same |
MX2010010209A (es) | 2008-03-18 | 2010-10-05 | Merck Sharp & Dohme | 4-hidroxipirimidina-5-carboxamidas sustituidas. |
-
2010
- 2010-06-21 US US13/379,536 patent/US8815865B2/en active Active
- 2010-06-21 JP JP2012518547A patent/JP2012532127A/ja not_active Withdrawn
- 2010-06-21 WO PCT/US2010/039289 patent/WO2011002623A1/en active Application Filing
- 2010-06-21 CA CA2766056A patent/CA2766056A1/en not_active Abandoned
- 2010-06-21 EP EP10794550.3A patent/EP2448583B1/en active Active
- 2010-06-21 MX MX2011013878A patent/MX2011013878A/es active IP Right Grant
- 2010-06-21 CN CN2010800287783A patent/CN102802629A/zh active Pending
- 2010-06-21 AU AU2010266558A patent/AU2010266558A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7323475B2 (en) * | 2003-06-06 | 2008-01-29 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and methods of use thereof |
US20070072876A1 (en) * | 2005-09-15 | 2007-03-29 | Orchid Research Laboratories Ltd. | Novel pyrimidine carboxamides |
US20080171756A1 (en) * | 2007-01-12 | 2008-07-17 | Shaw Antony N | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors |
Also Published As
Publication number | Publication date |
---|---|
EP2448583A4 (en) | 2012-12-05 |
MX2011013878A (es) | 2012-02-01 |
US8815865B2 (en) | 2014-08-26 |
EP2448583B1 (en) | 2014-06-25 |
JP2012532127A (ja) | 2012-12-13 |
CA2766056A1 (en) | 2011-01-06 |
EP2448583A1 (en) | 2012-05-09 |
AU2010266558A1 (en) | 2012-01-12 |
US20120108600A1 (en) | 2012-05-03 |
WO2011002623A1 (en) | 2011-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10851109B2 (en) | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | |
CN109983007A (zh) | 酰胺类衍生物抑制剂及其制备方法和应用 | |
CN102802629A (zh) | 取代的4-羟基嘧啶-5-甲酰胺 | |
EP4180431A1 (en) | Chemical compounds | |
CN115057855B (zh) | 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 | |
CN115515947B (zh) | Shp2抑制剂及其组合物和应用 | |
CN101951776A (zh) | 四氢-1h-吡咯稠合吡啶酮 | |
CN114375193B (zh) | 甲状腺激素受体β激动剂化合物 | |
WO2011133444A1 (en) | Substituted pyrimidines | |
KR20200013702A (ko) | α7니코틴성 아세틸콜린 수용체의 리간드 화합물 및 그 응용 | |
CN102459278A (zh) | 取代的-1,3,8-三氮杂螺[4.5]癸烷-2,4-二酮 | |
CN102802628A (zh) | 取代的4-羟基嘧啶-5-甲酰胺 | |
WO2023072301A1 (zh) | 吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途 | |
CN116239606A (zh) | 一种吡咯磺酰类衍生物、及其制备方法与应用 | |
EP4166553A1 (en) | Alkenyl pyrimidine compound, preparation method therefor, and application thereof | |
CN115785088A (zh) | 作为sos1抑制剂的化合物及其应用 | |
CN109134433A (zh) | 一种抑制rock的化合物及其应用 | |
CN111909147B (zh) | Dna-pk抑制剂 | |
US11555031B2 (en) | Compounds and methods for regulating insulin secretion | |
WO2024159211A1 (en) | Methods and compositions for treatment of obesity and diseases associated with fat cell enlargement | |
CN118119625A (zh) | 具有mat2a抑制活性的嘧啶-2(1h)-酮并二环类化合物及其用途 | |
WO2023280290A1 (zh) | 一种吡咯磺酰类衍生物、及其制备方法与应用 | |
CN117794923A (zh) | 苯并二噁烷类化合物、其制备方法与应用 | |
TW202334132A (zh) | Sarm1酶活性抑制劑及其應用 | |
CN113423709A (zh) | 三嗪酮并咪唑类化合物及其医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: SCHERING CORP (US) Free format text: FORMER OWNER: MSD CORP. Effective date: 20121206 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: New jersey, USA Applicant after: MERCK SHARP & DOHME Corp. Address before: New jersey, USA Applicant before: SCHERING Corp. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SCHERING CORP (US) TO: MSD CORP. |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20121206 Address after: New jersey, USA Applicant after: SCHERING Corp. Address before: New jersey, USA Applicant before: MERCK SHARP & DOHME Corp. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121128 |